Edition:
United States

Stemline Therapeutics Inc (STML.OQ)

STML.OQ on NASDAQ Stock Exchange Capital Market

10.68USD
3:59pm EST
Change (% chg)

$0.50 (+4.91%)
Prev Close
$10.18
Open
$10.19
Day's High
$10.88
Day's Low
$10.01
Volume
293,601
Avg. Vol
136,351
52-wk High
$20.55
52-wk Low
$7.86

Select another date:

Fri, Dec 21 2018

U.S. FDA approves Stemline Therapeutics' rare blood disease treatment

The U.S. Food and Drug Administration on Friday approved Stemline Therapeutics Inc's Elzonris for the treatment of a rare blood disease in adults and children aged two years and above.

UPDATE 2-U.S. FDA approves Stemline Therapeutics' rare blood disease treatment

Dec 21 The U.S. Food and Drug Administration on Friday approved Stemline Therapeutics Inc's Elzonris for the treatment of a rare blood disease in adults and children aged two years and above.

U.S. FDA approves Stemline Therapeutics' rare blood disease treatment

Dec 21 The U.S. Food and Drug Administration on Friday approved Stemline Therapeutics Inc's Elzonris for the treatment of a rare blood disease in adults and children aged two years and above.

Select another date: